Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Bosch and Randox Laboratories Allocate €150M for Development of PCR Tests on Vivalytic POC Platform

NextEdge Admin

09 Apr 2024

2 min 32 sec

Bosch Healthcare Solutions and Randox Laboratories have announced a joint investment of €150 million ($162 million) into research, development, and distribution of new point-of-care PCR tests for Bosch’s Vivalytic platform. This collaboration, which commenced in 2018, aims to establish market leadership in point-of-care testing by 2030. While the specific contributions from each partner remain undisclosed, they are committed to advancing the capabilities of the Vivalytic analysis device.

The primary focus of this investment will be on the development of a multiplex sepsis test, leveraging Bosch’s BioMEMS microelectromechanical and microfluidic technology. This cutting-edge technology enables the simultaneous execution of multiple reactions within a compact test cartridge, comparable in size to a smartphone. These cartridges facilitate automated testing, capable of assessing up to 250 genetic characteristics in a single run, delivering results in as little as 15 minutes.

The Vivalytic platform, unveiled in 2018, supports a variety of testing methodologies including cartridge-based endpoint PCR, quantitative real-time PCR, melt curve analysis, and microarray detection. By introducing a rapid sepsis test, Bosch and Randox are entering an already competitive market. Numerous other companies such as Inflammatix, Immunexpress, DiaSorin, Ad Astra Diagnostics, Siemens Healthineers, Nostics, and Cytovale have either developed or launched tests for sepsis detection.

Marc Meier, managing director of Bosch Healthcare Solutions, highlighted the significance of their fully automated molecular diagnostic PCR tests, emphasizing their ability to provide rapid clarity directly at the point of sample collection. This approach not only reduces waiting times but also alleviates pressure on the healthcare system, contributing to improved patient care.